

## NIH Public Access Author Manuscript

J Org Chem. Author manuscript; available in PMC 2009 August

#### Published in final edited form as:

J Org Chem. 2008 August 1; 73(15): 6045–6047. doi:10.1021/jo801024h.

## Total Synthesis of (*S*)-(+)-Tylophorine Via Enantioselective Intramolecular Alkene Carboamination

#### Wei Zeng and Sherry R. Chemler\*

Department of Chemistry, The University at Buffalo, The State University of New York, Buffalo, New York 14260

### Abstract



The enantioselective synthesis of (S)-(+)-tylophorine, a potent cancer cell growth inhibitor, has been accomplished in eight steps from commercially available 3,4-dimethoxybenzyl alcohol. A copper (II)-catalyzed enantioselective intramolecular alkene carboamination was employed as the key step to construct the chiral indolizidine ring.

The phenanthroindolizidine and phenanthroquinolizidine alkaloids have attracted human interest for centuries.<sup>1</sup> As early as the 1800s, the leaves of one of the plants, *Tylophora indica*, from which these compounds are isolated, was recommended in a medical text as an herbal remedy for conditions such as bronchitis, rheumatism, and dysentery in India.<sup>2</sup> Since the isolation of the major alkaloid, (*R*)-tylophorine, in 1935,<sup>3</sup> from *Tylophora indica*, over 60 compounds in this class have been isolated from the *Asclepiadaceae* and *Moraceae* plant families, found primarily in India and Japan.<sup>1</sup> The biological properties of these alkaloids range from cancer cell growth inhibition (in vitro and in vivo)<sup>1b,4</sup> and anti-inflammatory activity<sup>2</sup>, <sup>5</sup> to anti-ameobicidal<sup>6</sup> and anti-viral<sup>7</sup> activity. Structure–activity relationship studies focusing on the anticancer activity of these counpounds have drawn particular interest as many of them are low nanomolar inhibitors of cancer cell growth, including multi-drug-resistant cell lines. Notably, based upon the NCI's COMPARE<sup>8</sup> analysis,<sup>4d</sup> their mode of action appears to be different from other known anticancer compounds.

The structures of two particularly potent cancer cell growth inhibitors in vitro, (*S*)-tylophorine (**1**) and (*R*)-antofine (**2**), are illustrated in Figure 1. Although (*S*)-tylophorine is the unnatural enantiomer, it is a more potent inhibitor of cancer cell growth than (*R*)-tylophorine.<sup>4c,d</sup> Further investigations into the anticancer activity of (*S*)-tylophorine and (*R*)-antofine as well as tylophorinidine, a C(14) hydroxylated, C(2)-desmethoxy analog of tylophorine, revealed that they are only moderately potent tumor growth inhibitors in vivo, possibly because of suboptimal pharmakokinetics.<sup>4d,e,g</sup> Therefore, the development of a highly convergent synthesis useful for the discovery of more potent analogs is desirable.

It is noteworthy that a decrease in molecular complexity via removal of the indolizidine ring, dubbed the "limiting synthetic factor" by some researchers, led to substantial reduction of cancer cell growth inhibitory activity.<sup>9</sup> Thus, an efficient route to analogs with intact indolizidine rings is necessary.

A number of racemic synthetic routes to tylophorine and antofine have been published, some of them quite concise. <sup>1,4g</sup> Both the (*R*)- and (*S*)-tylophorine enantiomers have been synthesized selectively using the chiron approach, starting with either proline, <sup>10</sup> glutamic acid, <sup>11</sup> or pyroglutamate, <sup>12</sup> as well as the chiral auxiliary approach manifested in diastereoselective Grignard additions <sup>13</sup> and double Michael reactions, <sup>14</sup> respectively. Reported enantioselective syntheses of antofine make use of either the chiral pool (proline, 10b, <sup>7b</sup> pyroglutamate, <sup>15</sup> methyl lactate <sup>16</sup>) or asymmetric catalysis (phase transfer alkylation). <sup>17</sup> In the former case, <sup>7b</sup> however, epimerization of the indolizidine stereocenter is sometimes observed, while in the latter case the synthesis is somewhat lengthy. <sup>17</sup> Although a considerable amount of synthetic effort has been exerted toward these targets, we believed we could contribute uniquely to this area of research. We sought to develop a concise, convergent, and enantioselective route to these compounds that would be amenable to the synthesis of substituted indolizidine analogs where both the relative and absolute stereochemistry could be predictably installed. Herein is described our enantioselective synthesis of (*S*)-tylophorine, which uses a catalytic asymmetric carboamination reaction to install the required indolizidine stereocenter.

We have recently reported the use of copper(II) complexes in the efficient intramolecular carboamination of terminal alkenes.<sup>18</sup> These reactions result in the formation of polycyclic aromatic nitrogen heterocycles and can be performed both diastereoselectively<sup>18b</sup> and enantioselectively.<sup>18c</sup> We saw the carboamination disconnection in tylophorine, wherein sulfonamide **4** could undergo enantioselective carboamination to provide sultam **3**, which could be processed in short order to tylophorine (**1**) (Scheme 1). The sulfonamide serves a dual purpose in this reaction, both in increased reactivity (compared to the corresponding amide) and as a handle for enantioinduction (we have not been able to render the carboamination reactions of  $\gamma$ -alkenyl amides asymmetric yet).

Sulfonamide **4** is convergently synthesized from commercially available 3,4-dimethoxybenzyl alcohol. Conversion of 3,4-dimethoxybenzyl alcohol (**6**) to the bromide **7** followed by radical-induced dimerization<sup>19</sup> provided dimer **8** (Scheme 2). Oxidative cyclization and aromatization with phenyliodine(II-I)bis(trifluoroacetate) (PIFA) provided the known phenanthrene **9**.<sup>20</sup> Monosulfonylation with chlorosulfonic acid provided the necessary arylsulfonyl chloride **5**. <sup>21</sup> Careful control of the reaction temperature and equivalents of chlorosulfonic acid was necessary to avoid disulfonylation.

Coupling of 3-pentenyl amine (10) with arylsulfonyl chloride **5** provided sulfonamide **4** (Scheme 3). Enantioselective carboamination, promoted by substoichiometric (0.4 equiv) copper(II)-(*R*)-Ph-Box **11**, provided sultam **3** in 64% yield. Because of the poor solubility properties of this compound in the HPLC solvents hexanes/isopropanol, the enantiomeric excess was not measured at this point. Removal of sulfur dioxide under dissolving metal conditions (Li/NH<sub>3</sub>/DMSO) provided the known<sup>10a</sup> pyrrolidine **12**. The yield of this step is modest because removal of aryl methoxy groups also occurred under these conditions.<sup>22</sup> A range of reduction conditions were explored as alternative (Raney nickel, Ni(acac)<sub>2</sub>/*i*-Pr<sub>2</sub>Mg, <sup>23</sup> Mg/MeOH,<sup>24</sup> Na/NH<sub>3</sub>), but no superior conditions were identified. Pictet–Spengler reaction with formaldehyde closed the indolizidine ring, <sup>10a</sup> thereby providing synthetic (*S*)-tylophorine (**1**). The enantiomeric excess was measured to be 81% on chiral HPLC (Chiraclel AD-H). The NMR spectra of synthetic tylophorine matched the reported values, <sup>10</sup> and the optical rotation of (*S*)-(+)-**1**, [ $\alpha$ ]<sup>23</sup><sub>D</sub> = +62.1° (*c* 1.0, CHCl<sub>3</sub>) is in agreement with that reported previously, [ $\alpha$ ]<sup>21</sup><sub>D</sub> = +73.0° (*c* 0.7, CHCl<sub>3</sub>).<sup>10a</sup>

In summary, we have described a concise and convergent enantioselective synthesis of (*S*)-tylophorine. This route is amenable to the synthesis of either enantiomer of tylophorine from a common advanced intermediate and is also applicable to the synthesis of substituted indolizidine analogs via coupling of arylsulfonyl chloride **5** with a number of functionalized terminal  $\gamma$ -alkenyl amines. Structure–activity relationship studies of indolizidine-substituted analogs of tylophorine are in progress and will be reported in due course.

#### **Experimental Section**

#### Procedure for the Carboamination. (S)-2,3,6,7-Tetramethoxy-11,12,12a,13-tetrahydro-10*H*-9thia-9a-aza-cyclopenta[b]triphenylene-9,9-dioxide (3)

Cu(OTf)<sub>2</sub> (10.0 mg, 0.028 mmol, 0.4 equiv), 2,2-bis[(4R)-4-phenyl-2-oxazolin-2-yl]-propane (9.2 mg, 0.028 mmol, 0.4 equiv), and 2.5 mL of PhCF<sub>3</sub> were combined in a pressure tube equipped with a stir bar under Ar, and the mixture was stirred at 45–50  $^{\circ}$ C for 1 h to make the Cu(II) salt coordinate with the ligand completely. This mixture was then treated with  $K_2CO_3$ (9.5 mg, 0.069 mmol, 1 equiv), MnO<sub>2</sub> (18.0 mg, 0.206 mmol, 3 equiv), and 2,3,6,7tetramethoxyphenanthrene-9-sulfonic acid pent-4-enylamide (4) (30.6 mg, 0.069 mmol, 1 equiv), and then the tube was refreshed with Ar for 5 min, sealed, and heated at 120 °C in an oil bath for 24 h. Upon cooling to room temperature, the mixture was diluted with CHCl<sub>3</sub> (2.0 mL) and stirred for about 5 min. Filtration of the cooled solution and removal of the solvent in vacuo afforded a crude residue. Successive chromatography on SiO<sub>2</sub> (EtOAc/hexane, 3:1; CHCl<sub>3</sub>/EtOAc, 20:1) afforded purified sultam **3** (20.0 mg, 64%) as a light yellow solid. This reaction was performed on 0.344 mmol (0.153 g) of 4 as well, and a 61% yield was obtained. Mp 289–291 °C (decomposed);  $[\alpha]^{23}_{D} = +47.1 \circ (c \ 2 \text{ in } CH_2Cl_2)$ . <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  8.32 (s, 1 H), 7.79 (s, 1 H), 7.77 (s, 1 H), 7.30 (s, 1 H), 4.40–4.25 (m, 1 H), 4.14 (s, 3 H), 4.12 (s, 3 H), 4.10 (s, 3 H), 4.06 (s, 3 H), 3.80–3.70 (m, 1 H), 3.51–3.39 (m, 2 H), 3.20 (dd, J = 16.0, 8.0 Hz, 1 H), 2.52-2.40 (m, 1 H), 2.13-2.08 (m, 2 H), 2.00-1.90 (m, 1 H).NMR (75 MHz, CDCl<sub>3</sub>): *δ* 151.3, 150.0, 149.8, 149.7, 130.1, 129.6, 127.0, 125.0, 123.9, 120.9, 107.0, 105.3, 103.7, 103.4, 56.9, 56.5, 46.6, 33.2, 31.3, 23.0. IR (neat): 2959, 2938, 2253, 1619, 1533, 1515, 1476, 1466, 1421, 1278, 1264, 1247, 1213, 1199, 1147, 1044, 1005, 728, 607  $cm^{-1}$ . HRMS (EI) calcd for [M]<sup>+</sup> C<sub>23</sub>H<sub>25</sub>NO<sub>6</sub>S 443.1397, found 443.1407.

# Sulfonamide Reduction. (S)-2-(2,3,6,7-Tetramethoxyphenanthren-9-ylmethyl)-pyrrolidine (12)

The desulfonylation was performed by modification of the procedure reported by Evans.<sup>22</sup> Ammonia (10.0 mL) was condensed in a volume-marked two-neck flask containing sultam 3 (22.5 mg, 0.051 mmol) and dry THF/DMSO (1.0 mL, 1: 2) at -78 °C under Ar. Lithium metal (3.0 mg, 0.43 mmol, 8.4 equiv) was added over 15 min (1.0 mg of lithium per 5 min was added). After the mixture was stirred at -78 °C under Ar for 30 min, solid NH<sub>4</sub>Cl (1.0 g) was added, and the solution was warmed to room temperature and allowed to evaporate overnight. EtOAc (10 mL) and aqueous KOH (20%, 10 mL) were added to the resulting residue. The aqueous layer was extracted with EtOAc ( $3 \times 15$  mL), and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. The solvents were removed in vacuo, and flash chromatography of the resulting crude oil on SiO<sub>2</sub> using CH<sub>3</sub>OH/aqueous 37% NH<sub>4</sub>OH (3: 0.1) as eluent afforded 8.5 mg (44%) of (S)-2-(2,3,6,7-tetramethoxyphenanthren-9-ylmethyl)-pyrrolidine (12) as a light yellow oil, whose NMR spectrum was identical to that previously reported for  $12.^{10a} [\alpha]^{23} = +3.5^{\circ} (c)$ 0.94, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.84 (s, 1 H), 7.77 (s, 1 H), 7.48 (s, 1 H), 7.44 (s, 1 H), 7.19 (s, 1 H), 4.12 (s, 3 H), 4.11 (s, 3 H), 4.05 (s, 3 H), 4.03 (s, 3 H), 3.60–3.50 (m, 1 H), 3.19 (d, 2 H, J = 6.8 Hz), 3.18–3.08 (m, 1 H), 2.90–2.80 (m, 1 H), 1.91–1.88 (m, 2 H), 1.78–1.73 (m, 2 H), 1.60–1.50 (m, 1 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 149.4, 149.1, 132.4, 126.9, 126.1, 125.5, 125.2, 124.2, 108.6, 105.5, 104.0, 103.4, 59.2, 56.7, 56.6, 56.5, 56.4, 46.8, 40.8, 32.3, 25.5.

#### (S)-(+)-Tylophorine (1)

The Pictet-Spengler reaction was performed by a modification of the procedure as reported by Njoroge.<sup>10a</sup> To a solution of amine **12** (7.3 mg, 0.02 mmol) in EtOH (0.50 mL) were added 37% formaldehyde (0.11 mL) and concentrated HCl (11.0  $\mu$ L). The reaction mixture was refluxed for 2 days in the dark and then concentrated to dryness under reduced pressure. The residue was treated with 20% KOH (1 mL), the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2  $\times$  3 mL), and the combined organic layers were washed with water and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. Filtration and concentration in vacuo afforded the crude oil, which was purified by flash column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 20:1) to afford (S)-tylophorine (1) (6.7 mg, 89%) as light yellow solid. Mp 283–285 °C (lit. mp 282–284 °C, <sup>11</sup> 284–286 ° C<sup>10a</sup>).  $[\alpha]^{23}_{D} = +62.1^{\circ}$  (*c* 1.0 in CHCl<sub>3</sub>). Lit.<sup>10</sup>  $[\alpha]^{21}_{D} = +73^{\circ}$  (*c* 0.7 in CHCl<sub>3</sub>), ee = 81%, determined by HPLC analysis [Chiralcel AD-H, 15% IPA/hexane, 0.70 mL/min,  $\lambda = 254$  nm,  $t_{\rm R}$  (major) = 22.50 min,  $t_{\rm R}$  (minor) = 34.54 min]. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  7.81 (s, 2 H), 7.29 (s, 1 H), 7.14 (s, 1 H), 4.61 (d, 1 H, J = 16 Hz), 4.11 (s, 6 H), 4.05 (s, 6 H), 3.66 (d, 1 H, J = 14.4 Hz), 3.51-3.41 (m, 1 H), 3.34 (d, 1 H, J = 17.2 Hz), 2.90 (t, 1 H, J = 11.2 Hz), 2.48-322.46 (m, 2 H), 2.31–2.20 (m, 1 H), 2.10–2.00 (m, 1 H), 2.00–1.80 (m, 1 H), 1.80–1.70 (m, 1 H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 147.7, 147.5, 147.4, 125.3, 124.8, 123.3, 122.6, 122.4, 103.0, 102.5, 102.3, 102.1, 59.2, 55.0, 54.9, 54.1, 52.9, 32.7, 30.2, 20.6. IR (neat): 2957, 1717, 1602, 1535, 1515, 1472, 1441, 1425, 1416, 1262, 1249, 1213, 1195, 1150, 1016, 840, 770 cm<sup>-1</sup>. HRMS (EI) calcd for [M]<sup>+</sup>  $C_{24}H_{27}NO_4$  393.1935, found 393.1933. These data were in agreement with those reported. <sup>10–13</sup>

#### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

#### Acknowledgements

The National Institutes of Health (NIGMS) GM078383 is gratefully acknowledged for financial support of this work.

#### References

- 1. (a) Gellert EJ. Nat Prod 1982;45:50. (b) Li Z, Jin Z, Huang R. Synthesis 2001:2365. (c) Bhakuni DSJ. Indian Chem Soc 2002;79:203.
- Gopalakrishnan C, Shankaranarayan D, Kameswaran L, Natarajan S. Indian J Med Res 1979;69:513. [PubMed: 447392]
- 3. Rathnagiriswaran AN, Venkatachalam K. Indian J Med Res 1935;22:433.
- 4. (a) Donaldson GR, Atkinson MR, Murray AW. Biochem Biophys Res Commun 1968;31:104. [PubMed: 4869942] (b) Ali M, Ansari SH, Grever MR. Pharmazie 2001;56:188. [PubMed: 11234356] (c) Staerk D, Christensen J, Lemmich E, Duus JO, Olsen CE, Jaroszewski JW. J Nat Prod 2000;63:1584. [PubMed: 11087617] (d) Gao W, Lam W, Zhong S, Kaczmarek C, Baker DC, Geng YC. Cancer Res 2004;64:678. [PubMed: 14744785] (e) Gao W, Busson S, Grill SP, Gullen EA, Hu UC, Huang X, Zhong S, Kaczmarek C, Gutierrez J, Francis S, Baker DC, Yu S, Cheng YC. Bioorg Med Chem Lett 2007;17:4338. [PubMed: 17531481] (f) Shiah HS, Gao W, Baker DC, Cheng YC. Mol Cancer Ther 2006;5:2482. (g) Fu Y, Lee SK, Min HY, Lee T, Lee J, Cheng M, Kim S. Bioorg Med Chem Lett 2007;17:97. [PubMed: 17049857]
- Gopalakrishnan C, Shankaranarayanan D, Nazimudeen SK, Kameswaran L. Indian J Med Res 1980;71:940. [PubMed: 7419261]
- 6. Bhutani KK, Sharma GL, Ali M. Planta Med 1987;53:532. [PubMed: 2895482]
- (a) Xi Z, Zhang R, Yu Z, Ouyang D. Bioorg Med Chem Lett 2006;16:4300. [PubMed: 16759858] (b) Li H, Hu T, Wang K, Liu Y, Fan Z, Huang R, Wang Q. Lett Org Chem 2006;3:806.
- Paull, KD.; Hamel, E.; Malspeis, L. Cancer Chemotherapeutic Agents. Foye, WO., editor. American Chemical Society; Washington, DC: 1995. p. 9-45.

J Org Chem. Author manuscript; available in PMC 2009 August 1.

- 9. Wei L, Brossi A, Kendall R, Bastow KF, Morris-Natschke SL, Shi Q, Lee KH. Bioorg Med Chem 2006;14:6560. [PubMed: 16809043]
- (a) Nordlander JE, Njoroge FG. J Org Chem 1987;52:1627. (b) Fürstner A, Kennedy WJ. Chem Eur J 2006;12:7398.
- 11. Buckley TF, Rapoport H. J Org Chem 1983;48:4222.
- 12. Jin Z, Li SP, Wang QM, Huang RQ. Chin Chem Lett 2004;15:1164.
- 13. Comins DL, Chen X, Morgan LA. J Org Chem 1997;62:7435. [PubMed: 11671861]
- 14. Ihara M, Takino Y, Tomotake M, Kukumoto K. J Chem Soc, Perkin Trans 1990;1:2287.
- 15. Faber L, Wiegrebe W. Helv Chim Acta 1976;59:2201. [PubMed: 1017959]
- 16. Kim S, Lee T, Lee E, Lee J, Fan GJ, Lee SK, Kim D. J Org Chem 2004;69:3144. [PubMed: 15104454]
- 17. Kim SH, Lee J, Lee T, Park HG, Kim D. Org Lett 2003;5:2703. [PubMed: 12868894]
- 18. (a) Sherman ES, Chemler SR, Tan TB, Gerlits O. Org Lett 2004;6:1573. [PubMed: 15128239] (b) Sherman ES, Fuller PH, Kasi D, Chemler SR. J Org Chem 2007;72:3896. [PubMed: 17428100] (c) Zeng W, Chemler SR. J Am Chem Soc 2007;129:12948. [PubMed: 17918850] (d) Fuller PH, Chemler SR. Org Lett 2007;9:5477. [PubMed: 18044907]
- Barrero AF, Herrador MM, Quilez Del Moral JF, Arteaga P, Akssira M, Hanbali FE, Arteaga JF, Dieguez HR, Sanchez EM. J Org Chem 2007;72:2251. [PubMed: 17309310]
- 20. (a) Moreno I, Tellitu I, San Martin R, Dominguez E. Synthesis 2001:1161. (b) Moreno I, Tellitu I, Dominguez E, San Martin R. Eur J Org Chem 2002:2126.
- 21. Kanehara M, Oumi Y, Sano T, Teranishi T. Bull Chem Soc Jpn 2004;77:1589.
- 22. This side reaction has been previously observed: Evans P, McCabe T, Morgan BS, Reau S. Org Lett 2005;7:43. [PubMed: 15624973]
- 23. Milburn RR, Snieckus V. Angew Chem, Int Ed 2004;43:888.
- 24. Yokoyama Y, Matsumoto T, Murakami Y. J Org Chem 1995;60:1486.



**Figure 1.** Phenanthroindolizidine natural products.



Scheme 1. Retrosynthetic Analysis



Scheme 2. Phenanthrene Synthesis



Scheme 3. Completion of (S)-Tylophorine